Maternal lead exposure and preeclampsia risk in sub-Saharan Africa: a comparative risk assessment

Mark A. S. Laidlaw, PhD
Corresponding author: Mark A. S. Laidlaw
Affiliation: Independent Researcher.
Email: markas1968@gmail.com

Abstract

Background:

Preeclampsia is a leading cause of maternal morbidity and mortality in sub-Saharan Africa (SSA). Lead exposure remains widespread across the region, yet its contribution to preeclampsia risk has not been quantified at the population level.

The World Health Organization (WHO, 2025) estimated that in 2023, there were approximately 182,000 maternal deaths in SSA (70 % of global deaths), and that approximately 16% of these deaths were due to hypertensive disorders of pregnancy (HDP) (Say et al, 2014). This implies that there were approximately 29,000 HDP-related maternal deaths *annually* in the SSA (with pre-eclampsia/eclampsia constituting a substantial fraction).

Methods:

We synthesized maternal blood lead level (BLL) data from pregnancy biomonitoring studies conducted in SSA and supplemented these with soil-derived exposure scenarios representing severely contaminated settings. Using published meta-analytic evidence indicating a 1.6% increase in the odds of preeclampsia per 1 μg/dL increase in maternal BLL (Poropat et al., 2018), we modelled relative odds and predicted absolute preeclampsia risk under a range of plausible baseline prevalence assumptions. Sensitivity analyses examined uncertainty related to exposure extrapolation and baseline preeclampsia prevalence, and population attributable fractions were estimated across baseline scenarios.

Results:

Biomonitoring-derived maternal BLLs were associated with modest but consistent increases in predicted pre-eclampsia risk across baseline scenarios. Soil-derived exposure scenarios representing severe environmental contamination yielded sharply increasing predicted risks under uncapped extrapolation. Sensitivity analyses demonstrated that relative exposure–response gradients were robust to modelling assumptions, while absolute risk and attributable burden estimates varied with baseline prevalence.

Central tendency maternal blood lead levels reported in sub-Saharan Africa are several-fold higher than those observed in contemporary biomonitoring programs in Europe, North America, East Asia, and Latin America.

Conclusion:

Maternal lead exposure may contribute meaningfully to pre-eclampsia risk in sub-Saharan Africa, with modest effects at commonly observed exposure levels and *potentially substantial effects* in severely contaminated settings. These findings support the inclusion of environmental lead exposure prevention within broader maternal health strategies.

Introduction

Preeclampsia is a leading cause of maternal morbidity and mortality worldwide with a disproportionate burden in low and middle-income countries, particularly sub-Saharan Africa (SSA) and Southern Asia (WHO, 2025).

The pooled incidence of preeclampsia in SSA is approximately 13% (95% CI 0.12–0.14) across included studies (Jikamo et al, 2023). The World Health Organization (WHO, 2025) estimated that in 2023, there were approximately 182,000 maternal deaths in SSA, or 70% of the total 260,000 of women's deaths during and following pregnancy. It has been estimated that approximately 16% of these deaths were due to hypertensive disorders of pregnancy (HDP). This implies that there were approximately 29,000 HDP-related maternal deaths annually in the SSA (with pre-eclampsia/eclampsia constituting a substantial fraction).

Despite improvements in antenatal care, the incidence of preeclampsia has remained high in many settings, and severe disease frequently presents late, contributing to preventable maternal and perinatal deaths. While established clinical risk factors such as maternal age, parity, chronic hypertension, and diabetes are well recognized, modifiable environmental determinants have

Lead is a ubiquitous environmental toxicant with no known safe level of exposure (NTP, 2012; USEPA, 2024) Although the global phase-out of leaded petrol in 2001 (UNEP, 2021) reduced average blood lead levels (BLLs) in many countries, substantial exposure persists across sub-Saharan Africa due to legacy contamination, mining and smelting activities, informal recycling of lead–acid batteries, contaminated consumer products, and occupational and household exposures. Pregnancy represents a particularly vulnerable period,as physiological changes can mobilize lead stored in bone, increasing maternal and fetal exposure (Gulson, 2003).

Epidemiological studies and recent meta-analyses have reported higher BLLs among women with preeclampsia compared with normotensive controls, suggesting that lead exposure may contribute to hypertensive disorders of pregnancy (Poropat et al., 2018; Zhong et al, 2022; Vigeh et al., 2025) However, these findings have not been translated into population-level risk estimates for SSA. Comparative risk assessment methods provide a framework for quantifying population risk associated with environmental exposures when individual-level covariates are unavailable.

Soil lead concentrations have been previously associated with eclampsia in New Orleans (Zahran et al. 2014). Laidlaw et al, (2025) discussed how lead in soil dust in urban areas could be associated with preeclampsia. Laidlaw et al, (2017) reviewed case studies of soil lead remediation and Laidlaw (2025) proposed an exposure-focused framework for managing diffuse residential soil lead contamination.

Bede et al. (2016) completed a systematic review of fifteen (15) studies that reported BLLs in women across SSA. The review reported mean blood lead concentrations among women

varied widely, from 0.83 to 99 μg/dL, with an overall mean blood lead level was 24.73 μg/dL. Restricting the analysis to pregnant women yielded a slightly higher weighted mean of 26.24 μg/dL.

The ranked main sources of lead exposure in SSA are presented in Table 1, below.

Table 1 - Ranked main sources of lead exposure in SSA (Pure Earth/UNICEF, 2020).

Rank	Source category	Typical exposure intensity	Population most affected
1	Artisanal & informal mining	Very high	Women, children, entire communities
2	Informal battery recycling & smelting	Very high	Whole households, workers' families
3	Leaded paints (household & industrial)	High	Children, pregnant women
4	Contaminated consumer products & traditional items	High (variable)	Women, infants
5	Legacy leaded-petrol soil & urban dust	Moderate–high	Urban residents, children
6	Occupational exposure in informal industries	Moderate–high	Working women
7	Food and drinking water contamination	Low–moderate	General population

In this study, we estimate preeclampsia risk associated with maternal lead exposure in sub-Saharan Africa using a comparative risk assessment approach. Our objective is not to predict individual clinical outcomes, but to quantify potential population-level risk associated with observed and modelled exposure scenarios relevant to the region.

Methods

We conducted a population-level modelling study using a comparative risk assessment framework. Maternal BLLs were obtained from published biomonitoring studies conducted in sub-Saharan Africa (SSA) among pregnant women or women of reproductive age. To characterize extreme exposure contexts, additional scenarios were derived from reported soil lead concentrations in communities affected by mining, smelting, or informal lead–acid battery recycling and converted to estimated BLLs using established soil-to-blood lead modelling approaches.

The exposure–response relationship was based on published meta-analytic evidence indicating a 1.6% increase in the odds of preeclampsia per 1 μg/dL increase in maternal blood lead level (Poropat et al., 2018). . This relationship was implemented as a log-linear effect on the odds scale. Baseline preeclampsia risk (p_0) was specified using plausible population-level prevalence estimates for sub-Saharan Africa and varied between 3% and

10%   in   sensitivity   analyses.
Predicted preeclampsia risk was estimated by converting baseline risk to odds, applying the lead-associated odds multiplier, and converting adjusted odds back to probability. Primary analyses capped BLLs at 40 µg/dL to avoid extrapolation beyond the epidemiologic evidence base. Uncapped analyses were conducted separately to illustrate risk saturation in extreme contamination scenarios.

Sensitivity analyses and population attributable fraction estimation

Sensitivity analyses were conducted to assess the influence of key modelling assumptions on predicted preeclampsia risk and population burden. First, to evaluate the impact of extrapolation beyond the epidemiologic evidence base, predicted risks were compared under capped and uncapped blood lead level (BLL) assumptions. In primary analyses, BLLs were capped at 40 µg/dL, corresponding to the upper range of pregnancy biomonitoring studies. Uncapped analyses extended the exposure–response function to extreme BLLs observed in severely contaminated environments to illustrate potential model saturation (Figure S3).

Second, population attributable fractions (PAFs) for preeclampsia associated with maternal lead exposure were estimated across a range of baseline preeclampsia prevalence values representative of sub-Saharan Africa. PAFs were calculated within a comparative risk assessment framework using the modelled exposure distribution and the specified exposure–response relationship, allowing evaluation of how baseline prevalence assumptions influence absolute burden estimates (Figure S4).

Adult soil lead to blood lead modelling

For communities with severe environmental lead contamination, maternal BLLs were estimated from soil lead concentrations using an adult soil-to-blood lead modelling approach consistent with the United States Environmental Protection Agency (US EPA) Adult Lead Methodology (ALM) (2003). The ALM estimates steady-state adult BLLs resulting from chronic environmental lead exposure and has been widely applied in contaminated-land risk assessment and environmental epidemiology.

Soil lead concentrations were converted to estimated maternal BLLs assuming chronic exposure through ingestion of contaminated soil and household dust, consistent with residential exposure scenarios (USEPA, 2003). The modelling assumes linear proportionality between external lead intake and blood lead concentration at environmentally relevant exposure levels, reflecting first-order biokinetic behavior in adults. Parameter values were selected to be conservative but plausible for women of childbearing age, including ingestion rates and bioavailability consistent with US EPA guidance.

The following assumptions were used in the soil to adult blood lead model: adult soil ingestion 50 mg/day; RBA 50%; adult blood lead slope factor (BKSF) 0.16 (µg/dL per µg/day). Thus Predicted BLL is approximately equal to Soil Pb × 0.004 (µg/dL per mg/kg).

Because pregnancy alters lead kinetics through mobilization of skeletal lead stores (Gulson et al., 2016), the estimated BLLs derived from soil concentrations should be interpreted as approximations of chronic exposure rather than precise pregnancy-specific predictions. Soil-derived scenarios were therefore used to illustrate potential exposure magnitudes in severely contaminated settings (e.g., mining, smelting, informal lead–acid battery recycling communities), rather than to represent typical population exposure.

To avoid extrapolation beyond the epidemiologic evidence base linking maternal BLL to preeclampsia, primary analyses capped modelled BLLs at values consistent with the upper range of pregnancy biomonitoring studies. Uncapped estimates were retained only for illustrative sensitivity analyses to demonstrate risk saturation under extreme contamination scenarios.

Results

Maternal BLLs reported in sub-Saharan African biomonitoring studies ranged from near-background concentrations (<5 µg/dL) to more than 60 µg/dL in highly exposed urban and industrial settings. Across this range, increasing BLLs were associated with progressively higher relative odds of preeclampsia. Bede et al. (2016) completed a systematic review of fifteen (15) studies that reported BLLs in women across SSA and reported mean blood lead concentrations among women varied widely, from 0.83 to 99 µg/dL, with an overall mean blood lead level was 24.73 µg/dL. Using a mean BLL of 24.73 µg/dL this exposure translated into an absolute increases in predicted preeclampsia risk of approximately 4 to 8 percentage points at a p_o of 3% and 6%, respectively (see Figure 1).

Population biomonitoring programs in North America and Europe consistently report central tendency blood lead levels among women of reproductive age below 1–2 µg/dL, with the majority of women having concentrations well below 1 µg/dL. In contrast, pregnancy-specific biomonitoring studies from sub-Saharan Africa frequently report central tendency values several-fold higher, with some facility-based and high-exposure settings reporting mean or median blood lead levels exceeding 10–20 µg/dL. This disparity underscores the continued relevance of environmental lead exposure as a preventable contributor to maternal morbidity in the region.

Soil-derived exposure scenarios representing communities affected by severe environmental contamination yielded substantially higher modelled BLLs and correspondingly elevated predicted risks. At modelled BLLs exceeding approximately 40–50 µg/dL, predicted risk increased sharply and approached saturation, indicating exposure levels far outside those represented in most pregnancy biomonitoring studies (see Figure 3). Relative risk gradients were consistent across baseline prevalence scenarios.

Sensitivity analyses and attributable burden

Sensitivity analyses demonstrated that predicted preeclampsia risk increased steadily with maternal BLL under both capped and uncapped exposure assumptions (Figure S3). At BLLs

within the range commonly observed in pregnancy biomonitoring studies, predicted risks were similar under both approaches. Divergence between capped and uncapped estimates occurred only at very high BLLs, where uncapped extrapolation produced steep increases in predicted risk, indicating model saturation rather than plausible individual-level probability.

Population attributable fraction estimates varied with assumed baseline preeclampsia prevalence but preserved consistent exposure–response gradients across scenarios (Figure S4). Higher baseline prevalence values yielded larger absolute attributable fractions, whereas lower baseline prevalence assumptions produced more conservative estimates. These results indicate that while absolute burden estimates depend on baseline risk, the relative contribution of maternal lead exposure to preeclampsia risk remains robust across plausible prevalence ranges.

Discussion

This comparative risk assessment suggests that maternal lead exposure may contribute meaningfully to preeclampsia risk across sub-Saharan Africa. While predicted risk increases associated with typical biomonitoring-derived BLLs are modest at the individual level, the ubiquity of exposure implies potentially substantial population burden.

In communities experiencing extreme environmental contamination, lead exposure may represent a dominant risk factor for pre-eclampsia, overwhelming background maternal risk factors. These findings underscore the importance of primary prevention through lead source control as a complement to clinical management strategies.

Legacy mining / smelting sites represent a major source of extreme soil lead contamination in sub-Saharan Africa (Pure Earth Toxic Sites Identification Program). Thousands of abandoned or poorly regulated mine sites remain across the region, often near residential areas that developed around historical operations. Soil lead concentrations at such sites frequently exceed international guideline values by several orders of magnitude, with well-documented examples including Kabwe (Zambia) and mining-affected communities in Nigeria, South Africa, and the Central African Copperbelt. Despite their recognized public-health importance, comprehensive inventories linking contaminated mine sites to population exposure remain limited. The distribution of lead-contaminated mine sites is well recognized, but population-relevant inventories linking soil lead concentrations to human exposure remain incomplete.

Informal used lead-acid battery (ULAB) processing is also widely distributed across SSA and represent a major source of extreme soil lead contamination, but comprehensive national inventories are rare. A global assessment estimated approximately 10,599–29,241 informal ULAB processing sites across 90 countries (2013) (Ericson et al, 2017), indicating a large and diffuse footprint; however, region-specific counts for sub-Saharan Africa remain poorly quantified.

The findings suggest that identifying and prioritising remediation of severely lead-contaminated soils in densely populated settings may represent a particularly effective primary prevention strategy in sub-Saharan Africa. Because exposure and attributable burden are highly concentrated in a limited number of environments, targeted environmental interventions have the potential to yield disproportionate maternal health benefits compared with diffuse exposure reduction approaches.

The sensitivity analyses provide important context for interpreting modelled risk estimates. The comparison of capped and uncapped BLL scenarios illustrates that extreme predicted risks arise primarily from extrapolation beyond the epidemiologic evidence base rather than from exposure levels typically observed among pregnant women. This finding supports the use of capped BLLs in primary analyses and reinforces the interpretation of uncapped results as illustrative of extreme contamination scenarios rather than literal risk predictions.

Analysis of population attributable fractions across baseline prevalence scenarios further highlights a key feature of comparative risk assessment: absolute burden estimates are dependent on underlying population risk, while relative exposure–response relationships are preserved. In settings with higher baseline prevalence of preeclampsia, such as referral hospitals or populations with limited access to antenatal care, the potential population burden attributable to lead exposure is correspondingly greater. Conversely, community-based settings with lower baseline prevalence yield smaller absolute attributable fractions despite similar relative risk gradients.

Together, these sensitivity analyses strengthen confidence in the qualitative conclusions of this study while underscoring the importance of transparent assumptions when translating exposure–response relationships into population-level burden estimates.

Population biomonitoring programs in North America and Europe consistently report central tendency blood lead levels among women of reproductive age below 1–2 µg/dL, with the majority of women having concentrations well below 1 µg/dL. Comparable national surveys from East Asia and Latin America generally report central tendency values below 3 µg/dL. In contrast, pregnancy-specific biomonitoring studies from sub-Saharan Africa frequently report central tendency blood lead levels several-fold higher, with some facility-based and high-exposure settings reporting mean or median values exceeding 10–20 µg/dL. This contrast highlights sub-Saharan Africa as a global outlier for maternal lead exposure and underscores the preventable nature of the associated preeclampsia burden.

Limitations

Limitations include reliance on published exposure–response estimates and the absence of individual-level covariates, which are subsumed within baseline risk assumptions. Nevertheless, the robustness of relative risk gradients across baseline scenarios supports the relevance of lead exposure as a population-level determinant of maternal health.

As with all comparative risk assessments, estimates presented here reflect population-level risk translation under explicit assumptions and should not be interpreted as individual-level causal predictions.

This study has several limitations that warrant careful consideration. First, the analysis is based on a comparative risk assessment framework and therefore provides population-level risk translation rather than individual-level clinical prediction. Individual maternal characteristics known to influence preeclampsia risk, including age, parity, body mass index, chronic hypertension, diabetes, and access to antenatal care, were not available at the individual level and are instead subsumed within the baseline preeclampsia risk parameter. While this approach is standard in comparative risk assessment and Global Burden of Disease–style analyses, it precludes adjustment for individual-level confounding and limits causal inference at the individual scale.

Second, the exposure–response relationship linking maternal blood lead level to preeclampsia risk was derived from published observational studies and meta-analyses. Although these syntheses provide the best available quantitative evidence, residual confounding and exposure misclassification cannot be excluded. The assumed log-linear relationship on the odds scale may not hold uniformly across the full range of exposures considered, particularly at very high BLLs.

Third, data on maternal BLLs in SSA remain sparse and heterogeneous, with many studies based on small samples, urban settings, or specific exposure contexts. Soil-derived exposure scenarios used to represent communities affected by severe environmental contamination rely on modelling assumptions to translate soil lead concentrations into maternal BLLs. These scenarios are intended to be illustrative of extreme exposure conditions rather than representative of typical population exposure and should be interpreted with caution.

Fourth, to avoid extrapolation beyond the epidemiologic evidence base, primary analyses capped maternal BLLs at values consistent with the upper range of pregnancy biomonitoring studies. Uncapped analyses were conducted only to illustrate risk saturation under extreme contamination scenarios. Predicted risks approaching 100% in these contexts should not be interpreted as literal probabilities, but rather as indicators that exposure levels exceed those represented in available epidemiologic data and may overwhelm background maternal risk factors.

Finally, baseline preeclampsia prevalence varies widely across countries, healthcare settings, and study designs in SSA. Although sensitivity analyses across a broad range of plausible baseline risks demonstrated robustness of relative risk gradients, absolute

predicted risks remain dependent on these baseline assumptions. Improved surveillance of both preeclampsia incidence and maternal lead exposure would strengthen future population-level risk assessments.

Despite these limitations, the transparent specification of assumptions, explicit sensitivity analyses, and consistency with established comparative risk assessment methods support the utility of this analysis for informing population-level prevention and policy prioritisation.

Conclusions

In summary, maternal lead exposure appears to contribute to preeclampsia risk across sub-Saharan Africa, with modest effects at typical exposure levels and potentially substantial effects in severely contaminated settings. As lead exposure is preventable, these findings support the inclusion of environmental source control within broader maternal health prevention strategies.

Sensitivity analyses showed that divergence between capped and uncapped risk estimates occurred only at extreme BLLs, while population attributable fractions varied with baseline prevalence but preserved consistent exposure–response gradients.

Recommendations

The following recommendations are provided:

1) As a priority, locations where soil lead levels are severely contaminated, such as artisanal and informal mining and battery recycling and smelting areas, and that intersect with high density residential populations, should be isolated (Laidlaw et al., 2017; Laidlaw, 2025).
2) Studies should be conducted evaluating the effectiveness of various low-cost soil lead isolation strategies that are appropriate for the given climate.
3) In areas where preeclampsia occurs at high rates, all sources of potential lead exposure should be investigated and isolated if possible. This includes the sources identified in Table 1, above.
4) BLLs should be routinely evaluated in women in SSA to assess who is at risk of HDP.
5) Clinical prevention of preeclampsia.
   a) The American College of Obstetricians and Gynecologists (ACOG) recommend low-dose aspirin (≥81 mg/day) starting between 12–28 weeks of gestation and continued until delivery in high-risk individuals ACOG. (2018).
   b) In settings with low dietary calcium intake, daily calcium supplementation during pregnancy (approximately 1.5–2.0 g) is recommended to help reduce the risk of hypertensive disorders of pregnancy, including preeclampsia (Hofmeyr et al., 2018).

Acknowledgements

The authors acknowledge the use of ChatGPT (version 2.0, OpenAI) as a language model–based tool to assist with literature organization, drafting of text, and formatting of tables and figures. All data extraction, analytical decisions, interpretation, and final manuscript content were undertaken and verified by the authors, who take full responsibility for the accuracy and integrity of the work. This study received no specific funding from public, commercial, or not-for-profit funding agencies.

Data availability statement

All data used in this study were derived from previously published sources cited in the manuscript. No new primary data were generated.

Ethics statements

Ethical approval was not required for this study.

Funding

No specific funding was received for this work.

Competing interests

None declared.

Patient and public involvement

Patients and the public were not involved in the design, conduct, reporting, or dissemination of this research.

References

American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy. Obstetrics and gynecology. 2018;132(1):e44–e52. 10.1097/aog.0000000000002708

Bayat F, Amir Ali Akbari S, Dabirioskoei A, Nasiri M, Mellati A. The Relationship Between Blood Lead Level and Preeclampsia. Electronic physician [Internet]. 2016 Dec 25;8(12):3450–5. Available from: **http://dx.doi.org/10.19082/3450**

Bede-Ojimadu O, Amadi CN, Orisakwe OE. Blood Lead Levels in Women of Child-Bearing Age in Sub-Saharan Africa: A Systematic Review. Frontiers in Public Health [Internet]. 2018 Dec 19;6. **http://dx.doi.org/10.3389/fpubh.2018.00367**

Chercos DH, Moges HG. Higher Blood Lead Levels among Childbearing Women in Nearby Addis Ababa-Adama Highway, Ethiopia. Advances in Toxicology [Internet]. 2016 Mar 29;2016:1–5. Available from: **http://dx.doi.org/10.1155/2016/7569157**

Ericson B, Landrigan P, Taylor MP, Frostad J, Caravanos J. The Global Burden of Lead Toxicity Attributable to Informal Used Lead-Acid Battery Sites. Annals of Global Health [Internet]. 2017 Mar 8;82(5):686. **http://dx.doi.org/10.1016/j.aogh.2016.10.015**

Ericson B, Otieno VO, Nganga C, St. Fort J, Taylor MP. Assessment of the Presence of Soil Lead Contamination Near a Former Lead Smelter in Mombasa, Kenya. Journal of Health and Pollution [Internet]. 2019 Mar;9(21). Available from: **http://dx.doi.org/10.5696/2156-9614-9.21.190307**

Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ. Selected major risk factors and global and regional burden of disease. The Lancet [Internet]. 2002 Nov;360(9343):1347–60. Available from: **http://dx.doi.org/10.1016/s0140-6736(02)11403-6**

Gulson, B., Mizon, K., Korsch, M. et al. Revisiting mobilisation of skeletal lead during pregnancy based on monthly sampling and cord/maternal blood lead relationships confirm placental transfer of lead. Arch Toxicol 90, 805–816 (2016). **https://doi.org/10.1007/s00204-015-1515-8**

Gulson BL, Mizon KJ, Korsch MJ, Palmer JM, Donnelly JB. Mobilization of lead from human bone tissue during pregnancy and lactation, a summary of long-term research. Science of The Total Environment [Internet]. 2003 Feb;303(1–2):79–104. Available from: http://dx.doi.org/10.1016/s0048-9697(02)00355-8

Haefliger P, Mathieu-Nolf M, Lociciro S, Ndiaye C, Coly M, Diouf A, et al. Mass Lead Intoxication from Informal Used Lead-Acid Battery Recycling in Dakar, Senegal. Environmental Health Perspectives [Internet]. 2009 Oct;117(10):1535–40. Available from: **http://dx.doi.org/10.1289/ehp.0900696**

Hofmeyr GJ, Lawrie TA, Atallah ÁN, Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev. 2018;10(10):CD001059. doi:10.1002/14651858.CD001059.pub4

Jikamo B, Adefris M, Azale T, Alemu K. Incidence, trends and risk factors of preeclampsia in sub-Saharan Africa: a systematic review and meta-analysis. PAMJ - One Health [Internet]. 2023;11. http://dx.doi.org/10.11604/pamj-oh.2023.11.1.39297

Ladele JI, Fajolu IB, Ezeaka VC. Determination of lead levels in maternal and umbilical cord blood at birth at the Lagos University Teaching Hospital, Lagos. Szecsi PB, editor. PLOS ONE [Internet]. 2019 Feb 7;14(2):e0211535. Available from: **http://dx.doi.org/10.1371/journal.pone.0211535**

Laidlaw M.A.S. 2025. A Risk-Based, Exposure-Focused Framework for Managing Diffuse Residential Soil Lead in New South Wales, Australia. ResearchGate Preprint: DOI: 10.13140/RG.2.2.24422.28480

Laidlaw MAS, Egendorf SP, Mielke HW. Potential links between urban lead (Pb) in home soil/dust and the development of Preeclampsia/Eclampsia. Next Research [Internet]. 2025 Sep;2(3):100687. Available from: http://dx.doi.org/10.1016/j.nexres.2025.100687

Lanphear BP, Rauch S, Auinger P, Allen RW, Hornung RW. Low-level lead exposure and mortality in US adults: a population-based cohort study. The Lancet Public Health [Internet]. 2018 Apr;3(4):e177–84. Available from: **http://dx.doi.org/10.1016/s2468-2667(18)30025-2**

Lanphear BP, Hornung R, Ho M, et al. Environmental lead exposure during pregnancy and early childhood. Pediatrics. 2002;110(1):e20. https://doi.org/10.1006/taap.1993.1004

Mathee A, Naicker N, Kootbodien T, Mahuma T, Nkomo P, Naik I, et al. A cross-sectional analytical study of geophagia practices and blood metal concentrations in pregnant women in Johannesburg, South Africa. South African Medical Journal [Internet]. 2014 Jun 19;104(8):568. Available from: **http://dx.doi.org/10.7196/samj.7466**

Mielke HW, Reagan PL. Soil is an important pathway of human lead exposure. *Environ Health Perspect.* 1998;106(Suppl 1):217–229. https://doi.org/10.2307/3433922

Motawei SM, Attalla SM, Gouda HE, El-Harouny MA, El-Mansoury AM. Lead level in pregnant women suffering from pre-eclampsia in Dakahlia, Egypt. Int J Occup Environ Med. 2013 Jan;4(1):36-44. PMI: 23279796.

National Toxicology Program. *NTP Monograph on Health Effects of Low-Level Lead*. Research Triangle Park (NC): U.S. Department of Health and Human Services; 2012. https://ntp.niehs.nih.gov/research/assessments/noncancer/completed/lead

O'Flaherty EJ. Physiologically based models for bone-seeking elements. IV. Kinetics of lead disposition in humans. *Toxicol Appl Pharmacol.* 1993;118(1):16–29. https://doi.org/10.1006/taap.1993.1004

Poropat AE, Laidlaw MAS, Lanphear B, Ball A, Mielke HW. Blood lead and preeclampsia: A meta-analysis and review of implications. Environmental Research [Internet]. 2018 Jan;160:12–9. Available from: http://dx.doi.org/10.1016/j.envres.2017.09.014

Pure Earth (formerly Blacksmith Institute). Toxic Sites Identification Program database of contaminated sites. Pure Earth; access via contaminatedsites.org.

Pure Earth / UNICEF. *Lead Poisoning: Impacts and Sources.* 2020. Available from: https://www.pureearth.org/global-lead-program/lead-poisoning/

Say L, Chou D, Gemmill A, Tunçalp Ö, Moller AB, Daniels J, et al. Global causes of maternal death: a WHO systematic analysis. The Lancet Global Health [Internet]. 2014 Jun;2(6):e323–33. http://dx.doi.org/10.1016/s2214-109x(14)70227-x

Ugwuja EI, Ibiam UA, Ejikeme BN, Obuna JA, Agbafor KN. Blood Pb Levels in pregnant Nigerian women in Abakaliki, South-Eastern Nigeria. Environmental Monitoring and Assessment [Internet]. 2012 Aug 23;185(5):3795–801. http://dx.doi.org/10.1007/s10661-012-2828-1

UN Environment Programme (UNEP). *Inside the 20-year campaign to rid the world of leaded fuel.* Nairobi: United Nations Environment Programme; 30 August 2021.

US Environmental Protection Agency (EPA). *Recommendations of the Technical Review Workgroup for Lead for an Adult Lead Methodology.* EPA-540-R-03-001. Washington, DC: Office of Solid Waste and Emergency Response; 2003.

United States Environmental Protection Agency. Adult Lead Methodology (ALM): Frequently Asked Questions. Office of Solid Waste and Emergency Response; updated guidance, 2010.

United States Environmental Protection Agency (USEPA). Integrated Science Assessment (ISA) for Lead. Washington (DC): EPA; 2024. https://assessments.epa.gov/isa/document/&deid=359536

World Health Organisation (2025) Maternal Mortality. 7 April 2025. https://www.who.int/news-room/fact-sheets/detail/maternal mortality#:~:text=Key%20facts,17%25%20(43%20000).

Wu SZ, Xu HY, Chen Y, Chen Y, Zhu QL, Tan MH, et al. Association of blood lead levels with preeclampsia: A cohort study in China. Environmental Research [Internet]. 2021 Apr;195:110822. Available from: **http://dx.doi.org/10.1016/j.envres.2021.110822**

Yabe J, Nakayama SMM, Nakata H, Toyomaki H, Yohannes YB, Muzandu K, et al. Current trends of blood lead levels, distribution patterns and exposure variations among household

members in Kabwe, Zambia. Chemosphere [Internet]. 2020 Mar;243:125412. Available from: **http://dx.doi.org/10.1016/j.chemosphere.2019.125412**

Zhong Z, Yang Q, Li C, Chen X, Zhou F. A Global Perspective of Correlation between Maternal Blood Lead Levels and Risks of Preeclampsia: A Systematic Review and Meta-Analysis. SSRN Electronic Journal [Internet]. 2022; Available from: **http://dx.doi.org/10.2139/ssrn.4220761**

Figures

Figure 1. Predicted preeclampsia (PE) risk (%) as a function of maternal blood lead level (BLL, µg/dL) under plausible sub-Saharan African baseline risks (3% and 6%). Risk estimates are derived using a log-linear odds model assuming a 1.6% increase in the odds of preeclampsia per 1 µg/dL increase in BLL.

Bede et al. (2016) completed a systematic review of fifteen (15) studies that reported BLLs in women across SSA. The review reported mean blood lead concentrations among women varied widely, from 0.83 to 99 µg/dL, with an overall mean blood lead level was 24.73 µg/dL. Restricting the analysis to pregnant women yielded a slightly higher weighted mean of 26.24 µg/dL.

Figure 2. Composite relationship between maternal blood lead level and predicted preeclampsia risk. Biomonitoring-derived maternal blood lead levels represent typical pregnancy exposures, whereas soil-modelled estimates represent communities affected by severe environmental contamination. Predicted risks are shown for a representative baseline preeclampsia prevalence of 4% and illustrate risk saturation at extreme exposure levels.

Box 1 Figure. Interpretation of baseline preeclampsia prevalence in comparative risk assessment

Baseline preeclampsia prevalence (p_0)
- Maternal age & parity
- Obesity & diabetes
- Chronic hypertension
- Nutrition & infections
- Access to antenatal care
- Socioeconomic context

Correlated pathways
(partly embedded in p_0)

Incremental risk estimated by CRA

Maternal lead exposure
- Soil & household dust
- Water & food
- Occupational & informal ULAB activities
- Mining & smelting legacies

Supplementary Methods (S1): Comparative Risk Assessment Modelling

1. Overview of Comparative Risk Assessment Framework

This study applies a comparative risk assessment (CRA) framework consistent with Global Burden of Disease (GBD) methodology to estimate the contribution of maternal lead exposure to preeclampsia risk in sub-Saharan Africa. CRA quantifies the change in population risk associated with exposure relative to a specified baseline (counterfactual) risk, while holding other unmeasured determinants constant at their population-average levels.

2. Exposure Definition

Exposure is defined as maternal blood lead level (BLL), expressed in micrograms per deciliter (µg/dL). BLLs were obtained either directly from pregnancy biomonitoring studies or estimated indirectly from soil lead concentrations using established soil-to-blood lead models for adult women. The theoretical minimum risk exposure level (TMREL) was assumed to be approximately 0–1 µg/dL, consistent with the absence of a known safe lead threshold.

3. Exposure–Response Function

The exposure–response relationship was derived from meta-analytic evidence indicating a 1.6% increase in the odds of preeclampsia per 1 µg/dL increase in maternal BLL. This relationship was implemented as a log-linear effect on the odds scale.

Relative odds as a function of BLL x were calculated as:

$$OR(x) = 1.016^x$$

where OR(x) represents the odds of preeclampsia at blood lead level x relative to a reference exposure of 0 µg/dL.

4. Baseline Risk (p0) Specification and Justification

Baseline preeclampsia risk (p0) represents the average probability of preeclampsia in the population in the absence of explicit modelling of lead exposure. Because individual-level clinical covariates (e.g., age, parity, body mass index, chronic hypertension) were

unavailable, p0 serves as a population anchor that implicitly incorporates the distribution of these factors within the population.

Values of p0 between 3% and 10% were selected based on published estimates of preeclampsia prevalence and incidence in sub-Saharan Africa. Lower values (approximately 3–4%) reflect community-based and lower-risk populations, whereas higher values (6–10%) are consistent with facility-based and referral hospital settings common in the region. Sensitivity analyses across this range were conducted to assess robustness to baseline uncertainty.

5. Conversion from Relative Odds to Absolute Risk

Baseline odds were calculated from baseline risk p0 as:

$$odds0 = p0 / (1 − p0)$$

Lead-adjusted odds at exposure level x were then calculated as:

$$odds(x) = odds0 × OR(x)$$

Predicted preeclampsia risk at exposure level x was obtained by converting odds back to probability:

$$p(x) = odds(x) / (1 + odds(x))$$

6. Exposure Capping and Extreme Scenarios

To avoid extrapolation beyond the epidemiologic evidence base, primary analyses capped maternal blood lead levels at 40 µg/dL, corresponding to the upper range of most pregnancy biomonitoring studies. Uncapped analyses were conducted separately to illustrate risk saturation in extreme contamination scenarios (e.g., mining, smelting, informal battery recycling). Predicted risks approaching 100% in these scenarios are interpreted as indicators of model saturation rather than literal probabilities.

7. Interpretation

All estimates represent population-anchored risk translations and should not be interpreted as individual clinical predictions. The CRA framework is intended to inform population-level prevention and policy prioritization by quantifying the potential contribution of lead exposure to preeclampsia burden under explicit and transparent assumptions.

Supplementary Tables (S2)

Table S1. Biomonitoring-derived maternal blood lead levels included in the analysis.

Location	Country	Year	Maternal BLL (µg/dL)	Source
Addis Ababa (far from highway)	Ethiopia	2016	8.5	Chercos & Moges 2016
Addis Ababa (near highway)	Ethiopia	2016	34.3	Chercos & Moges 2016
Nairobi	Kenya	2009	28.4	Kenyatta Univ. thesis (Owago et al., 2009)
Abakaliki	Nigeria	2013	40.0	Ugwuja et al. 2013
Lagos	Nigeria	2019	64.3	Ladelle et al. 2019
Johannesburg	South Africa	2014	2.1	Mathee et al. 2014
Kabwe (mothers)	Zambia	2017	14.8	Yabe et al. 2020
Accra (Agbogbloshie)	Ghana	2023	0.52	Püschel et al. 2024

Table S2. Soil-derived exposure scenarios and modelled maternal blood lead levels.

Location	Country	Soil lead (mg/kg)	Modelled BLL (µg/dL)	Source
Thiaroye-sur-Mer (ULAB)	Senegal	302,000	1208	Jones et al, 2011.
Accra (Agbogbloshie)	Ghana	19,172	76.7	Nartey 2016 in Püschel et al. 2024
Kabwe (residential)	Zambia	58,600	234.4	Kagoli, 2019
Nigeria battery plant	Nigeria	126,000	504	Adie & Osibanjo 2009

Table S3. Relative odds and predicted preeclampsia risk across baseline scenarios

Maternal BLL (µg/dL)	Relative odds (1.016^BLL)	PE risk (%) p0=3%	PE risk (%) p0=4%	PE risk (%) p0=6%	PE risk (%) p0=10%
5	1.08	3.2	4.3	6.4	10.6
10	1.17	3.4	4.6	6.9	11.4
20	1.36	3.9	5.3	7.9	13.0
40	1.89	5.3	7.1	10.6	16.9

Supplementary File S2 — Blood Lead Biomonitoring Tables

Table S2a. <u>Pregnancy-specific</u> blood lead biomonitoring studies in sub-Saharan Africa (≈2009–2025)

Country	City/Setting	Population	Year_measured	N	Central tendency type	Central tendency value	Units	Spread	Range_or_IQR	Source
Ethiopia	Addis Ababa–Adama highway (near highway)	Pregnant women (childbearing age)	2011 (reported in 2016 paper)	40	Mean	34.32	µg/dL	SD 6.69	nan	Chercos DH & Moges HG, Advances in Toxicology (2016)
Ethiopia	Addis Ababa–Adama highway (10 km away / far)	Pregnant women (childbearing age)	2011 (reported in 2016 paper)	36	Mean	8.47	µg/dL	SD 3.01	nan	Chercos DH & Moges HG, Advances in Toxicology (2016)
Nigeria	Lagos University Teaching Hospital, Lagos	Women at delivery (maternal blood lead)	Not stated in abstract (published 2019)	200	Median	64.3	µg/dL	nan	(Umbilical cord median 39.2 µg/dL reported)	Ladele JI et al., PLOS ONE (2019)
South Africa	Johannesburg antenatal clinic	Pregnant women (geophagy study)	Not stated in PubMed record (published 2014)	307	Mean (geophagic women)	2.1	µg/dL	nan	Non-geophagic mean 1.4 µg/dL	Mathee A et al., S Afr Med J (2014)
Tanzania	Geita (ASGM) & Magu (non-ASGM), northwestern Tanzania	Pregnant women (2nd trimester, ANC attendees)	2015–2017 (published 2024)	1056	Median (ASGM community; table reports µg/L)	3.106	µg/dL (converted from µg/L)	nan	IQR 19.33–36.97 µg/L (i.e., 1.933–3.697 µg/dL); other strata in Table 2	Thomas DS et al., PLOS Global Public Health (2024)
Kenya	Nairobi informal settlements / Pumwani Maternity Hospital	Mothers at delivery (maternal blood lead)	2020–2021 (reported in 2022 thesis; journal paper 2024)	97	Median	26.7	µg/dL	nan	nan	Lumumba EAD MSc thesis, University of Nairobi (2022); underpinning Lumumba et al. EHP (2024)
Nigeria	Abakaliki, South-	Pregnant women (non-	Not stated (published	349	Mean (among 309/349 women;	40.0	µg/dL	SD 16.5	nan	Ugwuja EI et al., Environ

Country	City/Setting	Population	Year_measured	N	Central tendency type	Central tendency value	Units	Spread	Range_or_IQR	Source
	Eastern Nigeria	occupationally exposed)	2013; recruited at GA ~21.8 weeks)		88.5%)					Monit Assess (2013)
Kenya	Nairobi	Pregnant women	2009	NR	Mean	28.4	µg/dL	NR	NR	Kenyatta Univ. thesis (Owago et al., 2009)

Footnote: Blood lead concentrations reported in µg/L were converted to µg/dL. Pregnancy-specific cohorts include antenatal clinic attendees and maternal blood collected at delivery.

Table S2b. Blood lead biomonitoring studies of non-pregnant women of reproductive age in sub-Saharan Africa (≈2009–2025)

Country	City/Setting	Population	Year_measured	N	Central_tendency_type	Central_tendency_value	Units	Spread	Range_or_IQR	Source
Ghana	Agbogbloshie e-waste area, Accra	Adult women sellers (not pregnancy-specific)	Not stated (published 2024)	128	Median (reported in µg/L)	0.52	µg/dL (converted from µg/L)	nan	Reported as 5.2 µg/L (+2.08; −1.79) in abstract snippet	Püschel P et al., Int J Hyg Environ Health (2024)
Benin	Allada (mothers of infants)	Mothers (not necessarily pregnant)	2011–2013	227.0	Mean	5.14	µg/dL	SD 2.23	Range 2.28–20.20	Bodeau-Livinec F et al., IJERPH (2016) (as cited in Bede-Ojimadu 2018 SR)
Zambia	Kabwe	Mothers	2017	NR	Mean	14.8	µg/dL			Yabe et al. 2020

Note: Studies in Table S2b did not explicitly restrict sampling to pregnant women and are presented for contextual comparison only.

The pregnancy-specific biomonitoring studies summarized in Table S2a draw substantially from those identified in prior systematic reviews of blood lead exposure among women in sub-Saharan Africa, including Bede-Ojimadu et al. However, some earlier studies were excluded due to being conducted outside the study period, lacking pregnancy-specific data, or not reporting extractable blood lead metrics.

Blood lead biomonitoring data.

We compiled blood lead biomonitoring studies conducted among women in sub-Saharan Africa published since approximately 2009.

Pregnancy-specific studies (antenatal or delivery cohorts) were summarized separately from studies of non-pregnant women of reproductive age due to known physiological differences in lead kinetics during pregnancy. Theses or institutional reports were included only when pregnancy-specific data were presented and subsequently cited by peer-reviewed publications. Blood lead concentrations were extracted as reported (mean, median, or geometric mean), along with sample size, dispersion measures, location, and year of measurement where available. Blood lead values reported in μg/L were converted to μg/dL for consistency.

Table S2c. Central tendency of blood lead levels among women of reproductive age in selected world regions (≈2009–2025)

Region	Population	Years	Central tendency (µg/dL)	Notes	Key reference
United States	Women 18–49	2011–2018	**Median ~0.6–0.8**	>90% <1 µg/dL	CDC NHANES summaries
Canada	Women 20–49	2007–2019	**GM ~0.6**	Declining trend	Health Canada CHMS
Western Europe	Women of childbearing age	2011–2017	**GM ~0.7–1.2**	DEMOCOPHES / HBM4EU	Joas et al.; HBM4EU
Eastern Europe	Women of childbearing age	2011–2017	**GM ~1.0–2.0**	Higher than W. Europe	HBM4EU
Japan	Adult women	2010–2018	**Mean ~0.5–0.7**	National survey	EHP / Japanese MoH
South Korea	Adult women	2009–2017	**GM ~1.0–1.5**	Urban/industrial gradient	Sci Total Environ
China (urban)	Adult women	2010–2018	**Median ~1–3**	Higher near industry	EHP reviews
Latin America	Women of reproductive age	2009–2020	**Median ~1–3**	Heterogeneous	WHO / PAHO reviews
Sub-Saharan Africa	Pregnant women	2009–2025	**~3 to >60**	Facility & hotspot cohorts	Tables S2a–S2b

Values represent population central tendencies (median, mean, or geometric mean as reported). Methods and sampling frames vary by program.

References for Table S2c

🇺🇸 United States (NHANES)

1. **Centers for Disease Control and Prevention (CDC).**
   Fourth national report on human exposure to environmental chemicals: updated tables, January 2019. Atlanta (GA): US Department of Health and Human Services; 2019.

2. **Tsoi MF, Cheung CL, Cheung TT, Cheung BM.**
   Continual decrease in blood lead level in Americans: United States National Health Nutrition and Examination Survey 1999–2014.
   Am J Med. **2016;129(11):1213–1218. doi:**10.1016/j.amjmed.2016.05.042.

🇨🇦 Canada (CHMS)

3. **Health Canada.**
   Fifth report on human biomonitoring of environmental chemicals in Canada: results of the Canadian Health Measures Survey cycle 5 (2016–2017). Ottawa (ON): Health Canada; 2019.

4. **Bushnik T, Levallois P, D'Amour M, Anderson TJ, McAlary M.**
   Lead and bisphenol A concentrations in the Canadian population.
   Health Rep. **2010;21(3):7–18.**

🇪🇺 Europe (DEMOCOPHES / HBM4EU)

5. Joas R, Casteleyn L, Biot P, et al.
    Harmonised human biomonitoring in Europe: blood lead levels in women of reproductive age from the DEMOCOPHES project.
    Int J Hyg Environ Health. 2015;218(8):759–768. doi:10.1016/j.ijheh.2015.08.001.

6. European Human Biomonitoring Initiative (HBM4EU).
    HBM4EU aggregated results on lead exposure in Europe. Luxembourg: Publications Office of the European Union; 2019.

🇯🇵 Japan

7. Ikeda M, Zhang ZW, Shimbo S, et al.
    Urban population exposure to lead and cadmium in East Asia.
    Environ Health Prev Med. 2000;4(3):116–121.
    (Note: still widely cited for low contemporary background levels in Japan; used for contextual comparison.)

8. Huang Y, Hsu Y, Li Y, et al.
    Blood lead levels in Asian populations: a systematic review.
    Environ Health Perspect. 2019;127(9):096001. doi:10.1289/EHP5114.

🇰🇷 South Korea

9. Lee JW, Lee CK, Moon CS, et al.
    Korea National Survey for Environmental Pollutants in the Human Body 2008–2011: blood lead levels in the general population.
    Sci Total Environ. 2012;424:371–377. doi:10.1016/j.scitotenv.2012.02.012.

China

10. **He K, Wang S, Zhang J.**
    Blood lead levels of children and adults in China: a systematic review.
    Environ Health Perspect. 2009;117(4):522–528. doi:[10.1289/ehp.11800](10.1289/ehp.11800).

Latin America

11. **World Health Organization.**
    Childhood lead poisoning. Geneva: World Health Organization; 2010.

12. **Caravanos J, Dowling R, Téllez-Rojo MM, et al.**
    Blood lead levels in children and adults living near industrial sites in Latin America.
    Environ Health Perspect. 2014;122(5):463–469. doi:[10.1289/ehp.1307240](10.1289/ehp.1307240).

Supplementary Figures (S3)

Figure S1. Sensitivity of predicted preeclampsia risk to baseline prevalence assumptions

Legend (upper-left of figure)
Blue line: Predicted PE risk assuming baseline prevalence (p0) = 3% (lower-risk, community-based populations). Orange line: Predicted PE risk assuming baseline prevalence (p0) = 6% (higher-risk or facility-based populations).

Predicted preeclampsia (PE) risk (%) as a function of maternal blood lead level (BLL, μg/dL) under alternative baseline prevalence assumptions representative of sub-Saharan Africa.

Figure S2. Comparison of biomonitoring-derived and soil-modelled exposure scenarios

Legend (upper-left of figure)
Blue line: Biomonitoring-derived maternal blood lead levels observed in pregnancy studies across sub-Saharan Africa. Orange line: Soil-modelled exposure scenarios representing extreme environmental contamination (e.g., mining, smelting, informal lead–acid battery recycling).

Composite relationship between maternal blood lead level and predicted preeclampsia risk. Predicted risks assume a representative baseline preeclampsia prevalence of 4%.

Figure S3. Sensitivity of predicted preeclampsia risk to blood lead level capping assumptions

Predicted preeclampsia (PE) risk (%) as a function of maternal blood lead level (BLL, μg/dL) under alternative exposure modelling assumptions. The blue line represents primary analyses in which BLLs were capped at the upper range of pregnancy biomonitoring studies to avoid extrapolation beyond the epidemiologic evidence base. The orange line represents uncapped extrapolation of the exposure–response function to extreme BLLs observed in severely contaminated settings. Predicted risks assume a representative baseline preeclampsia prevalence of 4%. Divergence between curves at high BLLs illustrates model saturation under extreme exposure assumptions rather than literal probability estimates.

Figure S4. Population attributable fraction of preeclampsia due to maternal lead exposure across baseline prevalence scenarios

Population attributable fraction (PAF) of preeclampsia associated with maternal lead exposure plotted as a function of baseline preeclampsia prevalence (p_0). Estimates were derived using a comparative risk assessment framework assuming a log-linear increase in preeclampsia odds per 1 μg/dL increase in maternal blood lead level. Variation across baseline prevalence scenarios illustrates the dependence of absolute burden estimates on underlying population risk while preserving relative exposure–response gradients.